Schwartz et al., 2013 - Google Patents
Prospective studies of total and ionized serum calcium in relation to incident and fatal ovarian cancerSchwartz et al., 2013
- Document ID
- 10402348146847500633
- Author
- Schwartz G
- Skinner H
- Publication year
- Publication venue
- Gynecologic Oncology
External Links
Snippet
OBJECTIVE: Biological markers that could aid in the detection of ovarian cancer are urgently needed. Many ovarian cancers express parathyroid hormone-related protein, which acts to raise calcium levels in serum. Thus, we hypothesized that high serum calcium levels might …
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 [Ca] 0 title abstract description 128
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/543—Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation not covered by G01N21/00 or G01N22/00, e.g. X-rays or neutrons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schwartz et al. | Prospective studies of total and ionized serum calcium in relation to incident and fatal ovarian cancer | |
| US20230314436A1 (en) | Methods for the detection and treatment of lung cancer | |
| Minami et al. | Gustave Roussy immune score and Royal Marsden Hospital prognostic score are biomarkers of Immune-Checkpoint inhibitor for non-small cell lung cancer | |
| Johns et al. | Associations between repeated measures of maternal urinary phthalate metabolites and thyroid hormone parameters during pregnancy | |
| Zhang et al. | Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up | |
| Ichikawa et al. | Serum Wisteria floribunda agglutinin‐positive human Mac‐2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection | |
| Wieskopf et al. | Cyfra 21-1 as a biologic marker of non-small cell lung cancer: evaluation of sensitivity, specificity, and prognostic role | |
| Perseghin et al. | Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up | |
| Eliassen et al. | Plasma 25-hydroxyvitamin D and risk of breast cancer in women followed over 20 years | |
| Travis et al. | Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition | |
| Korse et al. | Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China | |
| Ermiah et al. | Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in libya | |
| Kaneko et al. | Potential tumor markers of renal cell carcinoma: α‐Enolase for postoperative follow up, and galectin‐1 and galectin‐3 for primary detection | |
| Naito et al. | Association of obesity and diabetes with serum prostate-specific antigen levels in Japanese males | |
| Fortunato | A new sensitive automated assay for procalcitonin detection: LIAISON® BRAHMS PCT® II GEN | |
| Hokka et al. | Psf3 is a prognostic biomarker in lung adenocarcinoma | |
| Li et al. | Association between maternal and umbilical cord serum cobalt concentration during pregnancy and the risk of preterm birth: the Ma'anshan birth cohort (MABC) study | |
| Lindemann et al. | Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey | |
| Pass et al. | Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma | |
| De Petris et al. | Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer | |
| Kiriu et al. | Prognostic value of red blood cell distribution width in non-small cell lung cancer treated with anti-programmed cell death-1 antibody | |
| Nimptsch et al. | Plasma insulin‐like growth factor 1 is positively associated with low‐grade prostate cancer in the Health Professionals Follow‐up Study 1993–2004 | |
| Cao et al. | Goitrogenic anions, thyroid-stimulating hormone, and thyroid hormone in infants | |
| Enko et al. | Iron status determination in individuals with Helicobacter pylori infection: conventional vs. new laboratory biomarkers | |
| Liang et al. | Significance of pretreatment red blood cell distribution width in patients with newly diagnosed glioblastoma |